Spyre Therapeutics (NASDAQ: SYRE) announced topline results from the rheumatoid arthritis sub-study of its Phase 2 SKYWAY trial evaluating SPY072 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE